Ribupatide
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apn
Fujian Shengdi Pharmaceutical Co · Phase 3 · Active, not recruiting · Enrollment 144
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HRS9531 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- HRS9531: endpoint not reported
- Placebo: endpoint not reported